Epsilogen, a global frontrunner in the development of innovative immunoglobulin E (IgE) antibodies for cancer treatment, has announced two key appointments as part of its ongoing company expansion. Ashley Nagle has been named Chief Business Officer, bringing her extensive experience in strategic partnerships and business development to the role. Additionally, Peter Finan, a current Non-Executive Director, has been appointed as Non-Executive Chairman.
These appointments come at a crucial time for Epsilogen as the company continues to make significant strides in the field of IgE antibody-based cancer therapies. With Nagle’s expertise in driving business growth and Finan’s deep understanding of the biotech industry, Epsilogen is well-positioned to advance its ground-breaking research and forge new collaborations to bring life-changing treatments to patients worldwide.